SCHEMBL16057337

SCHEMBL16057337

Cc1cccc(-c2ccc(Cc3cccnc3OC(=O)O)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 3/20 0.43
TRPV1 Q8NER1 1/20 0.43
MGLL Q99685 1/20 0.43
FFAR4 Q5NUL3 1/20 0.43
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
SUCNR1 Q9BXA5 1/20 0.41
WNT3A P56704 1/20 0.41
CYP17A1 P05093 2/20 0.40
CYP11B1 P15538 2/20 0.40
CYP11B2 P19099 2/20 0.40
MEN1 O00255 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
MME P08473 1/20 0.39
HCAR2 Q8TDS4 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP19A1 P11511 1/20 0.39
PTAFR P25105 1/20 0.39
PTGER2 P43116 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16057336 0.92 CYP17A1 (0.44) FFAR1TRPV1MGLLFFAR4PPARG
SCHEMBL14975892 0.88 MEN1 (0.42) FFAR1CYP17A1MEN1RAB9AKMT2A
SCHEMBL16056700 0.87 FFAR1 (0.44) FFAR1FFAR4WNT3AKMT2AKMO
SCHEMBL17557052 0.85 KMT2A (0.47) FFAR1FFAR4MEN1RAB9AKMT2A
SCHEMBL16056694 0.84 ABHD6 (0.43) FFAR1FFAR4WNT3A
SCHEMBL16057422 0.84 CYP17A1 (0.42) CYP17A1CYP11B1CYP11B2MEN1KMT2A
SCHEMBL16058415 0.82 MKNK1 (0.48) WNT3ACYP11B1CYP11B2CYP3A4CYP19A1
SCHEMBL16056979 0.81 FFAR4 (0.43) FFAR1MGLLFFAR4PPARGPPARA
SCHEMBL16057945 0.80 L3MBTL1 (0.42) RAB9A
SCHEMBL14975891 0.80 MEN1 (0.42) FFAR1CYP17A1CYP11B1CYP11B2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828338-B2 Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-28 US disclosed
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-10 US disclosed
WO-2014144836-A2 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS NAAA, FAAH, FAAH2 FFAR1 297/4885TRPV1 468/4885MGLL 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.